About.com Health

Share this article:
Company Profile
Silver Medal Winner for “Health Website of the Year” at the 2007 MM&M Awards, About.com Health is among the top health Web sites with more than 8 million visitors each month. About.com Health has the highest composition of women 25-54 and is the leader in many categories, like Arthritis, Pediatrics and Diet & Nutrition. (Source:Nielsen//NetRatings July 2007/@plan Summer 2007)

About.com is one the 15 most visited sites in the U.S. Each month, over 36 million unique visitors in the U.S. and 50 million worldwide trust About.com and its expert "Guides" to help them make more informed decisions on topics ranging from health, food, parenting and technology. Content on About.com is written by over 600 expert "Guides" who share their passions, expertise and how-to information in almost two million pieces of original content. This passion translates into reach. No other content site reaches more moms than About.com. We also reach more teens than MTV, more women than iVillage andmore men than ESPN. (Source: Nielsen//NetRatings July 2007)

Services and Offerings
Interactive opportunities include targeted media in over 600 categories, sponsorships, custom sites, promotions, mobile and podcasting.

If there is a way to reach a targeted consumer, About.com helps advertisers deliver those messages regardless of platform. Plus, our bedside manner is more like a visit from the family doctor, rather than a medical encyclopedia.
Share this article:

Next Article in News

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union